Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › upadacitinib

upadacitinib

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of upadacitinib

30 trials tracked of upadacitinib: 21 in phase 3 or 4 and 18 with published results. The most-cited published study has 509 citations.

30Trials tracked
21Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 1 Phase 3 20 Phase 2 9
  1. Phase 3 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 509 cited
  2. Phase 3 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Completed · 105 cited
  3. Phase 3 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Completed · 67 cited
  4. Phase 3 A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) Completed · 62 cited
  5. Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy Completed · 60 cited
  6. Phase 3 A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs Completed · 56 cited
Show 24 more trials
  1. Phase 3 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs Completed · 56 cited
  2. Phase 3 A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Completed · 55 cited
  3. Phase 3 A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Completed · 55 cited
  4. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone Completed · 55 cited
  5. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) Completed · 31 cited
  6. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug Completed · 31 cited
  7. Phase 3 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis Completed · 29 cited
  8. Phase 3 Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) Completed · 29 cited
  9. Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 29 cited
  10. Phase 3 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) Completed · 28 cited
  11. Phase 3 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies Completed · 15 cited
  12. Phase 3 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 3 cited
  13. Phase 4 A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis Completed
  14. Phase 3 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) Completed
  15. Phase 3 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis Completed
  16. Phase 2 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis Completed
  17. Phase 2 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Completed
  18. Phase 2 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis Completed
  19. Phase 2 A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed
  20. Phase 2 A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Completed
  21. Phase 2 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms Completed
  22. Phase 2 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis Completed
  23. Phase 2 A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone Completed
  24. Phase 2 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Upadacitinib and IL-23 inhibitors show favorable efficacy and tolerability in moderate-to-severe ulcerative colitis
Drug Pipeline Meta-analysis
Upadacitinib and IL-23 inhibitors show favorable efficacy and tolerability in moderate-to-severe ulcerative colitis New Data Compares Treatments for Moderate to Severe Ulcerative Colitis
This network meta-analysis evaluates Upadacitinib, Ustekinumab, Risankizumab, Guselkumab, and Mirikizumab for moderate-to-severe ulcerative …
New research compares several medications for ulcerative colitis, highlighting different options for achieving remission and managing side e…
Frontiers Oct 16, 2026
Cardiovascular risk for Janus kinase inhibitors in rheumatoid arthritis remains inconsistent across specific molecules
Drug Pipeline Sys. Review
Cardiovascular risk for Janus kinase inhibitors in rheumatoid arthritis remains inconsistent across specific molecules New data reveals specific risks for some rheumatoid arthritis drugs
This narrative review examines the cardiovascular safety of Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis and other …
New data shows that one specific rheumatoid arthritis drug carries a higher risk of heart problems for some patients.
Frontiers Sep 14, 2026
Upadacitinib shows rapid improvement in refractory acrodermatitis continua of Hallopeau
Rheumatology Sys. Review
Upadacitinib shows rapid improvement in refractory acrodermatitis continua of Hallopeau Upadacitinib Shows Promise for Treatment of Chronic Skin Condition
This case report and literature review describes a 54-year-old man with a 13-year history of isolated acrodermatitis continua of Hallopeau (…
A new case report shows how a specific medication helped a man with a rare, long-term skin condition and nail inflammation.
Frontiers Jul 25, 2026
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
Rheumatology Sys. Review
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Jul 18, 2026
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab
Rheumatology RCT
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab Trial shows upadacitinib outperforms adalimumab for rheumatoid arthritis patients
This randomized controlled trial of 492 patients with rheumatoid arthritis and prior TNFi failure found upadacitinib 15 mg daily superior to…
A new trial finds that upadacitinib works better than adalimumab for people with rheumatoid arthritis who did not respond well to previous t…
Jul 4, 2026
Upadacitinib 15 mg daily improves pruritus and skin sclerosis in a case of refractory lichen sclerosus
Gastroenterology Sys. Review
Upadacitinib 15 mg daily improves pruritus and skin sclerosis in a case of refractory lichen sclerosus JAK Inhibitor Upadacitinib Shows Promise for Lichen Sclerosus
This case report and brief literature review describes the use of upadacitinib 15 mg daily for a patient with refractory generalized lichen …
A single case report finds upadacitinib may help treat stubborn lichen sclerosus, with no side effects seen over 10 months.
Frontiers Jul 2, 2026
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis
Dermatology Sys. Review
Upadacitinib 30 mg tops JAK inhibitors for moderate-to-severe atopic dermatitis in network meta-analysis Upadacitinib Shows Highest Efficacy for Moderate to Severe Atopic Dermatitis
A systematic review and network meta-analysis of 9 RCTs (4261 adults) found upadacitinib 30 mg had the highest efficacy for EASI-75, IGA-AD …
A review of data from over 4,000 patients suggests upadacitinib may be the most effective oral treatment among several JAK inhibitors for se…
Jul 1, 2026
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata
Cardiology Sys. Review
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata One drug improved skin, hair, and pigment in one man
A 57-year-old man with severe, refractory skin conditions showed significant improvement in dermatitis, vitiligo, and hair loss on upadaciti…
A single patient with three skin conditions saw dramatic improvement after taking upadacitinib for one year.
Frontiers Jun 9, 2026
Meta-analysis of upadacitinib for rheumatoid arthritis finds similar efficacy for 15 mg and 30 mg doses
Allergy & Immunology Meta-analysis
Meta-analysis of upadacitinib for rheumatoid arthritis finds similar efficacy for 15 mg and 30 mg doses Upadacitinib improves rheumatoid arthritis symptoms in meta-analysis
This systematic review and meta-analysis of 5,237 participants with rheumatoid arthritis found that upadacitinib 15 mg and 30 mg significant…
A new analysis finds upadacitinib helps rheumatoid arthritis symptoms, but higher dose raises infection risk.
Frontiers May 20, 2026
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
Infectious Disease Meta-analysis
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Frontiers May 2, 2026
Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort
Neurology Cohort
Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort Study compares upadacitinib and other therapies for Crohn's disease remission
This retrospective cohort study of 218 individuals with Crohn's disease found a 94.1% clinical remission rate at 26 weeks for upadacitinib, …
Upadacitinib showed a 94.1% remission rate for Crohn's disease patients at 26 weeks, but this finding comes from a very small group of just …
Frontiers Apr 19, 2026
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months
Psychiatry Cohort
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Frontiers Apr 16, 2026

All upadacitinib Articles